India's Sun Pharma senior executives swap leadership roles

Chutes and Ladders

Mumbai-based Sun Pharmaceutical Industries has named Kal Sundaram CEO for India and emerging markets for the country's top drugmaker, while Abhay Gandhi was named head of the company's North American division, the Indian Express newspaper reported.

The new roles are an indirect swap of responsibilities, with Sundaram coming back from the U.S. at the start of next year from his job as head of Taro Pharmaceutical Industries, which Sun bought in 2010 from its Israel-based founders. Gandhi previously held the post of CEO of Sun's India and subcontinent business.

Sun founder and Managing Director Dilip Shanghvi remains in control of the firm. Last year, he embarked on a major consolidation effort following the purchase of Ranbaxy Laboratories that included fresh looks at manufacturing operations hit by quality and data issues highlighted by the U.S. FDA


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

In earnings for the year ended March 31, released in May, Sun--the world's fifth largest generics maker--said it was confident a massive reorganization to consolidate operations after its purchase of Ranbaxy Laboratories in 2014 were "on track."  In particular, the company lauded progress in the U.S. market.

- here's the story from the Indian Express

Related Articles:
India's Sun brings home Taro CEO as business plan accelerates


Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.